MAPK3, mitogen-activated protein kinase 3, 5595

N. diseases: 647; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.350 Biomarker phenotype BEFREE Phosphorylation of extracellular signal-regulated kinase 1/2 in subepidermal nerve fibers mediates hyperalgesia following diabetic peripheral neuropathy. 30583000 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.350 Biomarker phenotype BEFREE This study aimed to elucidate whether extracellular signal-regulated kinases (Erk1/2)/β-arrestin pathways are involved in the crack-induced hyperalgesia. 30641110 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.350 Biomarker phenotype BEFREE Moreover, CFA-induced sensory nerve growth, which involves the extracellular signal-related kinase (ERK1/2) signaling pathway and likely contributes to inflammation-induced hyperalgesia, was blocked with the Cav2.2 inhibitor. 31607850 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.350 Biomarker phenotype BEFREE However, the mechanism of opioid-induced hyperalgesia development and in particular the potential interplay between N-methyl-D-aspartate receptors and protein kinase C or calcium/calmodulin-dependent protein kinase II or extracellular signal-regulated kinase 1/2 in the development of remifentanil-induced hyperalgesia is unclear. 28714352 2018
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.350 PosttranslationalModification phenotype BEFREE This study was to investigate the role of p38 activation via ERK1/2 phosphorylation in neurons and microglia of the spinal trigeminal subnucleus caudalis (Vc) in the promotion of orofacial hyperalgesia induced by unilateral anterior crossbite (UAC) traumatic occlusion in adult rats. 27865869 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.350 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.350 Biomarker phenotype CTD_human Spinal ERK1/2 activation with capsaicin treatment correlated with the development of prolonged referred hyperalgesia. 12941468 2003